148401-42-7

Basic information

• Product Name: 2-(4-(4-CHLOROPHENOXY)PHENYL)ACETIC ACID
• Synonyms: 2-(4-(4-CHLOROPHENOXY)PHENYL)ACETIC ACID
• CAS NO: 148401-42-7
• Molecular Formula: C₁₄H₁₁ClO₃
• Molecular Weight: 262.69
• Product Categories: Aromatics, Miscellaneous Reagents
• Mol File: 148401-42-7.mol

Chemical Properties

• Boiling Point: 409.4±30.0 °C(Predicted)
• Appearance: /
• Density: 1.317±0.06 g/cm3(Predicted)
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: 2-(4-(4-CHLOROPHENOXY)PHENYL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(4-CHLOROPHENOXY)PHENYL)ACETIC ACID(148401-42-7)
• EPA Substance Registry System: 2-(4-(4-CHLOROPHENOXY)PHENYL)ACETIC ACID(148401-42-7)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 148401-42-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-(4-Chlorophenoxy)phenyl)acetic Acid is used as a key intermediate compound for the synthesis of tri-substituted thiazoles. These thiazoles act as Receptor for Advanced Glycation Endproducts (RAGE) antagonists, which are crucial in the treatment of Alzheimer's disease. By inhibiting the RAGE pathway, these antagonists can potentially slow down the progression of neurodegenerative disorders and improve the quality of life for patients.

Upstream product

• 69383-41-1 methyl 2-(4-(4-chlorophenoxy)phenyl)acetate 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 1415596-12-1 C₃₂H₂₈ClNO₂S 
• 1415596-14-3 C₂₅H₂₂ClNO₂S 
• 1415596-30-3 C₃₂H₃₇ClN₂O₂S 
• 1415596-28-9 C₃₃H₃₇ClN₂O₂S 
• 1415596-69-8 C₁₆H₁₆ClNO₃ 
• 1415596-70-1 C₁₈H₁₉ClO₂ 
• 1415596-71-2 C₁₈H₁₈Cl₂O₂ 
• 69383-41-1 methyl 2-(4-(4-chlorophenoxy)phenyl)acetate 

Relevant articles and documents

Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer's disease

A series of thiazole derivatives were designed, and prepared to develop RAGE antagonist for the treatment of Alzheimer's disease (AD). SAR studies were performed to optimize inhibitory activity on Aβ-RAGE binding. SAR studies showed that introducing an amino group at part A was essential for inhibitory activity on Aβ-RAGE binding. Compounds selected from Aβ-RAGE binding screening displayed inhibitory activity on Aβ transport across BBB. They also showed inhibitory activity against Aβ-induced NF-κB activation. These results indicated that our derivatives had a potential as therapeutic agent for the treatment of AD.

Barbituric acid derivatives

Derivatives of 5,5-disubstituted pyrimidine-2,4,6-trianones are disclosed. These compounds have antitumor and antimetastatic activity.

Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds

Compounds of formula I in which R1represents a substituted or unsubstituted phenoxy, phenylthio, phenylsulfinyl, phenylsulfonyl, phenylamino or phenylmethyl residue, and R2represents an optionally substituted aryl or heteroaryl resid